Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Generate Biomedicines, Inc.NASDAQ: GENB

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables of $0 in Q1 FY2026

Q1 FY2026 accounts receivables was $0.

Context

  • Accounts receivables amounted to 1.0% of revenue in FY2025, unchanged from a year earlier.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$308K+244.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+244.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
308K USD
Year-over-year change
+244.6%

Accounts Receivables vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's FY2025 accounts receivables of $308K is the 4th largest of the 5 companies compared; the peer median is $553K.
  • Its year-over-year change of +244.6% is the highest of 5, against a peer median of -37.4%.
  • Accounts receivables amounts to 1.0% of revenue for GENB, versus a peer median of 33.4%.
GENB Competitors Peer median
Accounts Receivables for GENB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABCLAbCellera Biologics Inc.LTM Sep 2026$43.84M +19.1%+34.8%64.6%
ABSIAbsci CorporationLTM Mar 2026$1.38M +207.1%—75.4%
STROSutro Biopharma, Inc.LTM Mar 2026$1.08M -93.9%-4.6%1.1%
GENBGenerate Biomedicines, Inc.FY2025$308K +244.6%—1.0%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$28K -97.6%+23.2%2.2%
Peer median (excluding GENB) $553K-37.4%+23.2%33.4%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.